Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

levodopa

The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.

INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.

Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.

“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”

To read more on this topic click here.

For more information on Parkinson’s medication please visit the EPDA website.


Read more:

Researchers create Parkinson’s-resistant stem cells

Memory loss could be an indication of Parkinson’s

Go Back

Share this story

Comments


Related articles


Sharon Krischer September post lead

Perspectives

Did trauma during childbirth set off my friend’s young-onset Parkinson’s?

Could a traumatic birth trigger Parkinson’s symptoms?

READ MORE
Maryum Ali with her father Muhammed Ali

Global update

10 of our favourite Parkinson’s Life stories from 2021

What has been your favourite article about Parkinson’s disease?

READ MORE
Nike Mag lead

Global update

Nike Mag auction raises nearly $7m for Parkinson’s cure research

100% of the $6.75m raised by Nike Mag auction will go to MJFF

READ MORE